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Abstract: Sarcopenia is the progressive generalized loss of skeletal muscle mass, strength, 
and function which occurs as a consequence of aging. With a growing older population, there 
has been great interest in developing approaches to counteract the effects of sarcopenia, and 
thereby reduce the age-related decline and disability. This paper reviews (1) the mechanisms of 
sarcopenia, (2) the diagnosis of sarcopenia, and (3) the potential interventions for  sarcopenia. 
Multiple factors appear to be involved in the development of sarcopenia including the loss of 
muscle mass and muscle fibers, increased inflammation, altered hormonal levels, poor  nutritional 
status, and altered renin–angiotensin system. The lack of diagnostic criteria to identify patients 
with sarcopenia hinders potential management options. To date,  pharmacological  interventions 
have shown limited efficacy in counteracting the effects of sarcopenia. Recent evidence has shown 
benefits with angiotensin-converting enzyme inhibitors; however, further randomized controlled 
trials are required. Resistance training remains the most effective intervention for sarcopenia; 
however, older people maybe unable or unwilling to embark on strenuous exercise training 
programs.
Keywords: aged, muscle function, sarcopenia
Background
Maintaining muscle function is vital to maintain functional independence. In our 
 growing older population, muscle mass and force reach their peak between the second 
and fourth decades of life and thereafter show a steady decline with age.1 Sarcopenia is 
a syndrome characterized by progressive generalized loss of skeletal muscle mass and 
strength. It is usually accompanied by physical inactivity, decreased mobility, slow gait, 
and poor physical endurance which are also common features of the frailty syndrome.2 
Rockwood et al3 described the concept of frailty as “a multidimensional syndrome 
which involves loss of reserves (energy, physical activity, cognition, and health) which 
gives rise to increased vulnerability”. Frailty involves a cumulative decline in multiple 
physiological systems including a decline in the neuromuscular system which is linked 
to the development of sarcopenia in later life. The loss of muscle mass during the  ageing 
process is clinically important as it leads to reduced strength and exercise capacity, 
both of which are required to undertake normal daily living activities. Moreover, loss 
of muscle mass is a strong predictor of mortality in later life.4
It has been estimated that up to 15% of people older than 65 years and as many as 
50% of people older than 80 years have sarcopenia.5 Sarcopenia has a major impact 
on public health and the cost in the united States alone was estimated at $18.5  billion 
in 2000.6 With the increasing number of older people worldwide, the cost is ever 
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 increasing. There has, therefore, been great interest in 
 developing approaches to counteract the effects of  sarcopenia 
and thereby help in reducing the age-related decline and 
disability.
What causes sarcopenia?
Understanding the mechanisms that have been implicated 
in the development of sarcopenia can help direct sarcopenia 
treatments. Research is still ongoing but as yet no primary 
cause of sarcopenia has been identified. Multiple factors 
appear to be involved in the development of sarcopenia 
 (Figure 1). A reduction in muscle strength is primarily linked 
to a reduction in overall muscle mass.7 This reduction in 
muscle mass may occur due to a combination of the loss of 
muscle fibers as well as muscle fiber atrophy with a preferen-
tial atrophy of type 2 fast twitch fibers. Denervation of motor 
units which is then reinnervated with slow motor units can 
lead to increased muscle fatigability.8 Although the overall 
biological mechanism of sarcopenia is not fully understood, 
observational studies have shown that satellite cells which 
are involved in muscle regeneration are much lower in older 
people and, therefore, could play a role in sarcopenia.9
Other factors including hormonal changes including 
growth hormone (GH) and insulin-like growth factor (IGF-1) 
and androgens which help regulate growth and development 
of skeletal muscle appear to decrease in old age. It has been 
suggested that the renin–angiotensin system may play a role 
in modulating muscle function. Circulating angiotensin 2 
is associated with muscle wasting, reduced IGF-1 levels, 
and insulin resistance and could, therefore, contribute to 
 sarcopenia.10 Sarcopenia is also associated with chronic 
inflammation, and observational studies have shown increased 
levels of proinflammatory cytokines, tumor necrosis factor-α, 
and interleukin-6 in aging muscle.11 Studies looking at treat-
ing sarcopenia have attempted to address some of the factors 
implicated in the development of sarcopenia and we discuss 
the evidence surrounding this in our review.
Diagnosis of sarcopenia
The first step in the management of sarcopenia is to diagnose 
the condition. Unfortunately, at present there are no standard-
ized diagnostic criteria for sarcopenia. Although sarcopenia is 
considered as a dynamic process incorporating both changes 
in muscle mass and function, many observational studies have 
concentrated on assessing changes in muscle mass. Table 1 sum-
marizes the measurement techniques, what they measure, and 
their limitations. Although magnetic resonance imaging (MRI) 
is considered to be the most accurate measure of muscle mass, 
the currently preferred method is dual energy X-ray absorpti-
ometry (DXA) as it measures both fat mass and bone mass and 
↓ Muscle mass 
↓ Muscle strength
↓ Motor units
↓ No. muscle fibers
↑ Muscle fiber 
atrophy
SARCOPENIA
Other factors
Nutrition
Hormones
Metabolic
Immunological
RAAS
↑ Weakness ↑ Disability
↑ Disability 
Loss of independence
Figure 1 Mechanism of sarcopenia. 
Abbreviation: RAAS, renin–angiotensin–aldosterone system.
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is useful for assessing appendicular muscle mass. DXA closely 
correlates with measurements achieved via MRI scanning.12 The 
main limitation with DXA is that it may  underestimate the extent 
of sarcopenia as it can overestimate skeletal muscle mass by as 
much as 8% due to difficulty in distinguishing muscle from water 
retention and muscle fat  infiltration.13 Bioelectric Impedence 
Analysis is a quick noninvasive method for  measuring body 
composition via tissue conductivity.14 However, its reliability has 
been called into question as measurements can vary depending 
on an individual’s hydration status, ethnicity, physical  fitness, 
and age.15
Baumgartner5 in 1998 proposed a method for  diagnosing 
sarcopenia. The degree of sarcopenia was measured by taking 
the muscle mass relative to a person’s height.  Appendicular 
skeletal mass (ASM) was measured in all four limbs with 
DXA. Individuals with ASM/height2 (kg/m2) of two stan-
dard deviations (SDs) below the mean for gender specific 
healthy younger adults were more likely to have sarcopenia. 
Janssen et al16 measured skeletal muscle mass using bioim-
pedence and defined sarcopenia as a skeletal muscle index 
(skeletal muscle mass/whole body mass × 100) less than 1 
SD below the mean for young adult values. These defini-
tions fail to incorporate measures of disability and physical 
performance.16
Since then attempts have been made to refine the  definition of 
sarcopenia. More recently, a joint effort has been made between 
the European Society on Clinical  Nutrition and Metabolism 
and the Special Interest Needs group on geriatric nutrition on 
cachexia – anorexia and chronic  wasting diseases.17 A diagnosis 
of sarcopenia was based on two of the following:
  i. A low muscle mass, ie, a percentage of muscle mass .2 
SDs below the mean measured in groups of young adults 
of the same sex and ethnic background.
ii. Low gait speed, ie, walking speed below 0.8 m/s in the 
4-meter walking test. However, this could be replaced 
with one well-established functional test utilized locally 
as part of a comprehensive geriatric assessment.
Although this definition includes measures of  functional 
performance and helps to eliminate variance between  ethnicity 
and sex, it fails to set age-specific populations. It has been 
suggested that a T-score system similar to that for  osteoporosis 
is needed to include reference values for  different populations. 
However, further refinement is required.
The main effect of loss of muscle mass is loss of strength. 
Low muscle strength is associated with increased mortality.18 
Although complex measures of power and torque are avail-
able, hand-held dynamometers to measure hand grip and 
quadriceps strength have been commonly used with good 
reproducibility and validity and are simple to use and can 
be easily used in the clinical setting.19
Physical performance measures can complement 
 measures of muscle mass and strength in the diagnosis of 
sarcopenia. The Short Physical Performance Battery assesses 
muscle function and strength using measures which are 
reproducible to activities of daily living. The assessment 
involves balance tests, a timed 4-meter walk, and timed chair 
rise which can be easily performed in the clinical setting. It 
can predict the risk of future disability and, therefore, may 
be useful in identifying people in the preclinical stage of 
sarcopenia who may benefit from interventions.20
Comorbidities and factors like pain from osteoarthritis 
which are unrelated to sarcopenia may limit performance and 
underestimate muscle strength. Fat mass may contribute to 
functional decline independent of muscle mass.21 Individuals 
with sarcopenic obesity (high fat mass and low muscle mass) 
are more susceptible to mobility problems and disability than 
those who are simply obese or sarcopenic.22 It is, therefore, 
imperative that sarcopenia is diagnosed under its paradigm as 
a dynamic process by assessing lean body mass and physical 
performance. As yet this may be more difficult to reproduce 
in a clinical setting.
The main difficulties in diagnosing sarcopenia are the 
lack of consensus in the definition of sarcopenia as well 
as the difficulty in measuring changes in muscle mass and 
Table 1 Measuring techniques for sarcopenia
Measuring techniques Measurements Comments
Muscle size
 CT Scan Muscle cross-sectional area Radiation exposure, expensive
 MRI Scan Muscle cross-sectional area expensive, availability of MRI
 BIA Tissue conductivity ? reliability
 Muscle circumferences Mid arm and calf circumference Measurements effected by subcutaneous fat
 DXA scan Total skeletal muscle mass Reliable, low radiation exposure
Physical performance
 SPPB Lower extremity function validated tool for older people
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; BIA, bioelectric impedence analysis; DXA, dual energy X-ray absorptiometry; SPPB, Short 
Physical Performance Battery.
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function over time in older people. In clinical practice, the 
diagnosis is often missed as it is usually made in patients 
who appear to have “small muscle mass”. Simple measures 
of muscle strength and physical performance measures can 
supplement clinical diagnosis for the early recognition of 
people at risk of disability.
Potential interventions  
for sarcopenia
exercise and physical activity
Physical activity refers to the body movement that is 
 produced by skeletal muscle contractions and that increases 
energy expenditure.23 Evidence has shown that older adults 
who are less physically active are more likely to have lower 
skeletal muscle mass and strength and are at increased risk 
of developing sarcopenia.24,25
In aerobic exercise, the larger muscles in the body move 
in a rhythmic manner for a prolonged period of time, whereas 
resistance exercise involves muscles working hard against an 
applied force or weight such as in weight-lifting. Both aerobic and 
resistance-type exercise training have shown to improve the rate 
of decline in muscle mass and strength with age (Table 2).26
Aerobic activity (swimming, running, and walking) has 
long been linked to improvements in cardiovascular fitness 
and endurance capacity. Although aerobic exercise is less 
likely to contribute to muscle hypertrophy, it can increase the 
cross-sectional area (CSA) of muscle fibers.27 Mitochondrial 
volume and enzyme activity increase after aerobic exercise 
demonstrate that muscle protein synthesis and muscle quality 
improve irrespective of age.28 Aerobic exercise can also reduce 
body fat including intramuscular fat which in turn improves 
the functional role of muscle relative to body weight.29
In contrast to aerobic exercise training, resistance exercise 
training appears to have a larger effect on augmenting 
muscle mass and strength and attenuates the development 
of sarcopenia.30,31 Improvements in muscle strength can be 
achieved with as little as one resistance exercise training 
session per week.32 Frontera et al33 demonstrated improve-
ments in muscle CSA by 11% as well as improvement in 
muscle strength (.100%) after a 12-week period of high 
intensity resistance exercise training in older men. Similar 
improvements were seen in muscle strength even in the 
people aged .90 years with as little as 10–12 weeks of 
training.34
Muscle hypertrophy occurs when muscle protein synthesis 
outweighs protein breakdown. Older people performing resis-
tance exercise show a marked increase in skeletal muscle protein 
synthesis without an increase in whole body muscle breakdown. 
Resistance training in older people increases both mixed-muscle 
protein synthesis and specific major  histocompatibility complex 
Table 2 Summary of treatment options
Intervention Effect Comments
exercise  
 Aerobic  
 Resistance 
Increased cardiovascular fitness with increased endurance  
Increases mitochondrial volume and activity
Pros: overall beneficial effects  
of exercise to individual  
Cons: motivation  
to exercise remains low 
Increased muscle mass and strength  
Increased skeletal muscle protein synthesis and muscle fiber size  
Improvement in physical performance
Nutritional supplement varying evidence of increased muscle mass and strength Pros: ensures good protein intake  
Cons: may reduce natural food intake
Hormone therapy  
 Testosterone  
 estrogen  
 Growth hormone
varying evidence of increased muscle mass and strength Cons: masculinization of women;  
increased risk of prostatic cancer in men
Poor evidence of increased muscle mass but not function Cons: risk of breast cancer
Some evidence for increased muscle mass. varying evidence 
for increased muscle strength
Cons: side effects including fluid  
retention, orthostatic hypotension
vitamin D variable evidence for increased muscle  
strength
Reduced falls in nursing home residents
Pros: fracture reduction; possible  
cardiovascular benefits
ACe inhibitors Some evidence for increased exercise capacity Pros: other cardiovascular benefits  
Cons: renal function needs monitoring
Creatine variable evidence of increased muscle strength  
and endurance especially when combined with exercise
Cons: reports of nephritis
Potential new treatments  
 Myostatin antagonists  
 PPAR [δ] agonist  
 AICAR
 
No trials in older people  
No human trials  
No human trials
Abbreviations: PPAR-δ, peroxisome-proliferator-activated receptor-δ; AICAR, 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside; ACe, angiotensin-converting 
enzyme.
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synthesis to the same levels as younger adults.35 Evidence points 
to increases in size of both type 1 and type 2 muscle fibers 
which could explain the improvements in muscle strength and 
endurance.33,36 More recently, it has been reported that when using 
moderate  levels of resistance exercise training, improvements in 
muscle strength and size in healthy older people were comparable 
to muscle strength seen in younger individuals. Roth et al37 dem-
onstrated that 6 months of whole body resistance  training in older 
people (65–75 years) produced gains in muscle CSA similar to 
those achieved in younger individuals aged 20–30 years.
Progressive resistance training (PRT) is the most com-
monly used resistance therapy in older people. A Cochrane 
review of 121 randomized controlled trials of PRT in older 
people showed that doing PRT 2–3 times per week improved 
physical function, gait speed, timed get-up and go, climbing 
stairs and balance, and more importantly had a significant 
effect on muscle strength especially in the high intensity 
training groups.38
The majority of studies have shown that resistance 
 exercise training must be carried out at a high intensity 
in order to show substantial improvements in muscle 
strength.33,36,37 In contrast, Vincent et al39 performed a 
26-week study in older healthy adults at both low and high 
intensity resistance exercise training programs and found 
only a modest improvement in thigh muscle strength in the 
high intensity resistance exercise training group.
Resistance exercise training appears to be relatively safe to 
perform even in participants with multiple comorbidities and 
can help in prevention of falls.40 Resistance exercise increases 
muscle CSA as well as type 2 (fast twitch) muscle fibers, which 
leads to overall improvement in muscle power and the ability 
to improve physical functioning. As a result, this can lead to 
enhanced ability to perform activities of daily living, preventing 
in functional decline and  disability. Even in very old nursing 
home residents, resistance  exercise  training showed substantial 
improvements in muscle fiber CSA (3%–9%), muscle strength 
(.100%) as well as  improvements in physical performance such 
as gait speed and stair climbing.36,38 However, participation in 
regular exercise training requires motivation by the individual 
which may be difficult for some older individuals; therefore, 
nonexercise interventions may offer a useful alternative.
Nutrition
Many older adults do not consume sufficient amounts of dietary 
protein which leads to a reduction in lean body mass and 
increased functional impairment.41 The  current  recommended 
dietary allowance (RDA) of protein is 0.8 g/kg/day, almost 40% 
of people .70 years do not meet this RDA.42 Taking a low 
protein diet below the RDA leads to a significant decline in 
muscle strength and muscle mass in older women.43 However, 
even older people who take the recommended RDA for protein 
continue to have a negative nitrogen balance and may require a 
diet containing a higher protein content than the RDA to main-
tain their skeletal muscle.44 Protein and energy supplementa-
tion may increase muscle strength even in very old people in 
the short term, but a Cochrane review has found no definite 
functional benefit of nutritional supplementation.45–47
Although older people who exercise have increased pro-
tein requirements, studies investigating whether nutritional 
supplementation in combination with resistance training can 
augment muscle strength gains in older people have yielded 
inconsistent results. One randomized controlled trial in 
nursing home residents undergoing resistance training over 
10 weeks found that an additional 360 calories supplement 
increased leg muscle strength.36 Another study investigating 
the effect of dietary protein supplementation in combination 
with a 12-week resistance training period found that protein 
supplementation increased muscle mass but not muscle 
strength.48 Nutritional supplementation may also result in 
an overall decrease in voluntary food intake and adherence 
to the supplements can be a problem.47
Testosterone
Testosterone is secreted by the Leydig cells in men and ovar-
ian thecal cells in women.49 Testosterone appears to increase 
muscle mass and increase muscle protein synthesis.50 It also 
increases the number of satellite cells in both animals and 
humans which are essential for muscle cell function.51
A substantial number of older men are hypogonadal. 
Hypogonadism has been defined as a total testosterone con-
centration of ,9.26 nmol/L (2 SD below the mean for healthy 
young men). As a result, approximately 20% of men .60 years 
and 50% men .80 years are  categorized as hypogonadal.52 Cir-
culating testosterone is highly bound to sex  hormone binding 
globulin (SHBG) and as SHBG increases with age, the total 
amount of bioavailable  testosterone decreases. This phenom-
enon has been termed the “male menopause” or “andropause” 
in older men.  Testosterone decreases gradually at a rate of 
1% per year and  bioavailable testosterone by 2% per year in 
males from the age of 30 years.53 The overall reduction of 
testosterone is associated with loss of muscle strength, muscle 
mass, a reduction in bone mineral density, and increased risk 
of fracture risk following falls.54,55
Evidence to support testosterone supplementation is 
variable. Gruenewald and Matsumoto56 analyzed 29 random-
ized controlled trials investigating the effects of testosterone 
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replacement in older men. Some studies found an increase in 
lean body mass and hand grip strength but no effect on knee 
extension and flexion strength.56 Other studies have shown 
up to 25% increase in leg strength in as little as 4 weeks of 
therapy.57 Some  studies have found no increase in muscle 
strength or f unction but an improvement in lean body mass.58 
 Testosterone  supplementation has been shown to increase the 
size of the prostate gland in men.59 This could be detrimental 
to men older than 60 years in which the prevalence of early 
stage prostate cancer is already high.60 The Baltimore Longi-
tudinal Study on Aging involving 781 men showed a positive 
correlation between prostate cancer and the blood concentra-
tion of free testosterone levels. The likelihood of acquiring 
a high risk prostate cancer in men .65 years doubled for 
every 0.1 unit increase in free testosterone.61 This along with 
other  potential side effects of testosterone therapy like fluid 
 retention, gynecomastia, polycythemia, and sleep apnea limit 
its usefulness as a treatment for sarcopenia.59,62,63
estrogens
The menopause is linked to reduced concentrations of cir-
culating estradiol in middle aged and older women. There 
appears to be impaired muscle performance during the 
postmenopausal period when ovarian hormone production 
has decreased.64 It is easy to hypothesize that estrogens may 
play a role in sarcopenia in older women.
The effect of hormone replacement therapy (HRT) in women 
is controversial. HRT may attenuate the loss of muscle mass 
which occurs in the perimenopausal period.65 Estrogen replace-
ment therapy has only modest benefits on muscle composition 
and this may not translate to improved physical functioning.66 
HRT combined with resistance training may have a role in 
improving lower extremity function; however, more evidence 
is needed.67 HRT has been implicated as a risk factor for breast 
cancer and is, therefore, not recommended for sarcopenia.68
Growth hormones
GH is required for maintenance of muscle and bone. GH 
exerts most of its anabolic actions through IGF-1 which is 
synthesized in the liver for systemic release. IGF-1 helps 
improve muscle function by increasing production of muscle 
satellite cells as well as stimulating production of muscle 
contractile proteins.69 Not only do GH and IGF-1 levels 
decline with age, the amplitude and frequency of pulsatile 
GH release is also significantly reduced.70
Despite a number of studies which have assessed the 
administration of GH supplementation, there is still an ongo-
ing debate as to the use of GH supplementation on muscle 
mass, strength, and physical performance. The strongest 
evidence for the use of GH supplementation appears to be 
in states of reduced GH secretion. In younger GH deficient 
adults, GH supplementation for 3 years increased thigh 
muscle mass, strength, and improved exercise capacity.71 
However, in healthy non-GH deficient older people results 
are more controversial. Some studies have shown an increase 
in muscle mass but no improvement in muscle strength, 
whereas others have shown an increase in both muscle mass 
and strength after administration of GH supplementation.72–74 
The failure of exogenous GH to mimic the pulsatile pattern of 
normal GH secretion has been blamed for the negative results. 
Alternative potential hormonal interventions include the use 
of GH releasing hormone which was found to have only a 
small improvement in muscle strength in older men.75
It is well known that muscle strength increases as a result 
of resistance exercise training in older adults.30,33 It was hypoth-
esized that the combination of GH replacement and exercise 
training may have a synergistic effect on muscle function 
in older people. However, results proved disappointing and 
the addition of GH supplementation does not augment the 
improvements in skeletal muscle brought about by exercise 
alone.76,77 Low GH levels alone, therefore, may not be respon-
sible for the leveling off of muscle strength seen in older exer-
cising people and that other pathways may be involved.
As it currently stands the evidence for the use of GH 
supplementation to counter the effects of sarcopenia in older 
people is weak. Moreover, the majority of trials involving 
GH replacement therapy in older people have reported a high 
incidence of side effects, including increased fluid retention, 
gynecomastia, orthostatic hypotension, and carpel tunnel 
syndrome.72,78
vitamin D
Vitamin D levels decline with age and cutaneous vitamin 
D levels are up to four times lower in older compared with 
younger individuals.79 It is known that vitamin D plays an 
important role in bone and muscle metabolism. Several 
mechanisms have been suggested for the role of vitamin D in 
muscle function. Vitamin D binding to the vitamin D receptor 
found in skeletal muscle promotes muscle protein synthesis 
and enhances calcium uptake across the cell  membrane.80 
Low vitamin D levels result in atrophy predominantly of the 
type 2 (fast twitch) muscle fibers in common with sarcope-
nia.81 Low levels of vitamin D have been found to be associ-
ated with an increase in sarcopenia.82 A myopathy has been 
reported in severe vitamin D deficiency.83 In older people low 
vitamin D levels may produce functional problems including 
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proximal muscle weakness, difficultly rising from a chair, dif-
ficulties in ascending stairs, and axial balance problems.84
The evidence for a benefit in physical performance with 
supplementation of vitamin D is controversial. Some studies 
have shown an improvement in muscle strength with inter-
mittent dosing and others have shown small gains in lower 
extremity strength and less body sway with daily dosing.85 
This improvement has been hypothesized as the mechanism 
behind a fall reduction of 23%–53% in older nursing or 
residential home residents given vitamin D in addition to a 
reduction in fractures.86–88
Conversely, other studies have found no benefits on 
physical function, falls risk or quality of life with vitamin D 
supplementation in vitamin D deficient people.89–91 The differ-
ence in findings between studies may in part be attributed to 
differences in the dose of vitamin D used with better outcomes 
seen when higher doses are used.92 It has also been suggested 
that there is a gender difference in outcomes with women 
standing to gain more from  supplementation.92  Variations 
between study populations may also affect outcomes with 
the biggest improvements in muscle function and physical 
performance seen in institutionalized older people.
The prevalence of vitamin D insufficiency (25(OH)D 
levels ,40 nmol/L) in older people is high between 50% 
and 75% especially in the northern latitudes and low levels 
have been found even in summer months.93–95 A European 
epidemiological study showed the prevalence of vitamin D 
deficiency in older adults aged 71–76 years was 36% in older 
men and 47% in older women.96 It is recommended that 
25(OH)D levels ,40 nmol/L requires supplementation and 
25(OH)D levels of .75 nmol/L is the level for optimum 
bone and muscle health.97 The recommended daily intake of 
vitamin D is between 400 IU and 600 IU per day which may 
be inadequate to raise serum vitamin D levels to a desirable 
level .70 nmol/L.98,99 Studies have shown that in order to 
achieve optimal levels of 75–100 nmol/L of 25(OH)D doses 
between 700 and 1,000 IU would be needed.90 In the United 
States, fortification of food such as milk and orange juice is 
mandatory, whereas in the UK only margarine is  fortified with 
vitamin D. The question of whether it should be  mandatory 
for UK food products to be fortified with vitamin D remains 
controversial.
Although it is plausible to associate low levels of vitamin D 
with a reduction in muscle strength and  physical function, 
the evidence for supplementation has been  inconsistent. 
Safety issues surrounding vitamin D supplementation in 
older people include increased risk of nephrolithiasis and 
hypercalcemia.100,101 Further large randomized controlled 
trials are required with a longer follow-up period in order 
to assess the safety profile of vitamin D supplementation in 
older people before it is recommended as a treatment for 
sarcopenia in clinical practice.
Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme (ACE) inhibitors have long 
been used as a treatment in primary and secondary prevention 
in cardiovascular disease as well as  secondary stroke preven-
tion. It has now been suggested that ACE inhibitors may have a 
beneficial effect on skeletal muscle. ACE inhibitors may exert 
their beneficial effects on skeletal muscles through a number of 
different mechanisms (Figure 2). ACE inhibitors may improve 
muscle function through improvements in endothelial function, 
metabolic function anti-inflammatory effects, and angiogenesis 
thereby improving skeletal muscle blood flow. ACE inhibitors 
can increase mitochondrial numbers and IGF-I levels thereby 
helping to counter sarcopenia.102–107 People with the II geno-
type of the ACE gene who have low serum ACE levels show 
an increased response to physical endurance.108,109 Therefore, 
lowering serum ACE levels with ACE inhibitors may have a 
beneficial effect on physical function. Observational studies 
have shown that the long-term use of ACE inhibitors was 
associated with a lower decline in muscle strength and walk-
ing speed in older hypertensive people and a greater lower 
limb lean muscle mass when compared with users of other 
antihypertensive agents.110,111 Several studies have shown that 
ACE inhibitors improved exercise capacity in younger people 
with heart failure and this was also confirmed in older people 
with heart failure,110,112,113 no improvement in grip strength.114 
Although this could be largely attributed to improvements in 
cardiac function, skeletal muscle atrophy is also associated 
with chronic heart failure so the evidence in muscle gains 
should not be discounted.
Few interventional studies using ACE inhibitors for 
 physical function have been undertaken. One study looking 
at functionally impaired older people without heart failure 
has shown that ACE inhibitors increase 6-minute walk-
ing distance to a degree comparable to that achieved after 
6 months of  exercise training.115 Another found that ACE 
inhibitors increased exercise time in older hypertensive 
men.116 However, a study comparing the effects of nifedipine 
with ACE inhibitors in older people found no difference 
between treatments in muscle strength, walking distance, or 
functional performance.117 It is possible that frailer subjects 
with slower walking speeds, who have a tendency to more 
cardiovascular problems, benefit more. This is reflected in 
the fact that adults with severe peripheral vascular disease 
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significantly increase their walking time following treatment 
with ACE inhibitors.118
Further evidence is required before recommending ACE 
inhibitors to counter the effects of sarcopenia. However, ACE 
inhibitors are associated with cardiovascular benefits and 
as older people frequently have underlying cardiovascular 
problems these agents are already commonly prescribed.
Creatine
Creatine plays an important role in protein metabolism and 
cellular metabolism. It has been hypothesized that creatine 
increases the expression of myogenic transcription factors 
such as myogenin and myogenic regulatory factor-4, which 
increases muscle mass and strength.119 Creatine supplemen-
tation increases muscle phosphocreatine levels leading to a 
decrease in muscle relaxation time.120,121 This may increase 
the ability to perform high-intensity exercise as well as 
enhance muscle protein synthesis, lean skeletal muscle mass, 
and strength during periods of high intensity training.
To dates, several studies of creatine supplementation 
have shown increased muscle strength and power in younger 
men and women but few studies have looked at the effect 
of creatine supplementation in older people. Some  studies 
have reported no effect of creatine supplementation on 
muscle strength or function.122,123 However, others have 
reported increments in muscle mass and increased muscle 
power without adverse effects.122,124 There is controversy 
over whether creatine supplementation increases the benefits 
of resistance training alone in older people. Some studies 
have found no added benefit of creatine supplementation to 
resistance exercise training and other studies have found a 
small increase in lean tissue mass with no residual benefit 
once resistance training was stopped.125–127
Creatine is a natural ingredient of food and the main 
source is from meat products with an average daily intake 
of 1 g/day. However, creatine supplementation may increase 
the risk of interstitial nephritis highlighting the need for 
particular caution about its use in older people.128 Creatine 
is not currently recommended for sarcopenia.
Myostatin
Myostatin is a natural inhibitor of growth factor. It was  initially 
discovered when mutations of the myostatin gene was found 
to correlate with exaggerated muscle  hypertrophy.129 The 
myostatin gene appears in skeletal muscle cells and functions 
as a negative regulator of muscle growth,  antagonism of 
which increases satellite cell  proliferation.130 In animal 
models, it appears that over expression of myostatin induces 
extensive muscle loss.131 Polymorphisms of the myostatin 
gene in humans correlated with measure of muscle mass, 
strength, and physical performance.132
Agents which target the myostatin pathway may be useful 
in increasing muscle mass and, therefore, play a vital role in 
muscle wasting disorders as well as sarcopenia of old age. 
Muscle fibers
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↑ muscle fibre area
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Neurohormonal
↑ sympathetic activity
↑ neuromuscular 
transmission
Angiogenesis
↑ endothelial cell 
growth
↑ skeletal muscle blood
flow
Metabolic
↑ insulin sensitivity
↑ glucose uptake 
↑ mitochondrial 
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↓ muscle loss
Inflammation
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Figure 2 effects of ACe inhibitors on skeletal muscle. 
Abbreviations: ACe, angiotensin-converting enzyme; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
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Phase II trials have been carried out in muscular dystrophy 
and initial results have shown that MYO-29, a recombinant 
antibody to myostatin, had good safety and tolerability pro-
file.133 Another potential therapeutic approach in development 
is a soluble activin type 2B receptor that binds to the myo-
statin and, therefore, reducing its availability. Initial results 
in mice have shown an increase in muscle weight larger than 
those achieved with myostatin inhibitors.134
Inhibition of myostatin with follistatin (myostatin antago-
nist) may have potential therapeutic benefits in the treatment of 
sarcopenia. Although myostatin deficiency increased muscle 
mass in mice it impaired, the structure and function of the mus-
cle tendons thereby making the tendons smaller, stiffer, and 
more brittle.135,136 Older people who are already at increased 
risk of contraction induced injury may find it more difficult to 
sustain regular exercise. Further studies are required.
Other potential therapies
Following suggestions of a role for both the  peroxisome-prolife
rator-activated receptor-δ (PPAR-δ) and adenosine monophos-
phate (AMP)-activated protein kinase in regulating the metabolic 
and contractile characteristics of myofibers, studies looking at 
the effect of modulating these receptors have been carried out 
in mice. The PPAR-δ agonist GW1516 significantly increases 
exercise capacity when combined with exercise but not in sed-
entary mice. However, the activator of AMP-activated protein 
kinase called AICAR (5-aminoimidazole-4-carboxamide-1-
beta-4-ribofuranoside) increases exercise performance by 44% 
even in sedentary mice and may possible be the “exercise in a 
pill” for older people.137 It remains to be verified if these drugs 
are suitable for human beings especially older people.
Conclusion
Sarcopenia is an ever increasing global health concern that 
needs to be urgently addressed. Public awareness of the impor-
tance of physical activity need to be increased and  exercise 
programs designed for older people should be developed. 
Although the primary aim would be to prevent the occurrence 
of the sarcopenia, like many other medical problems, we are 
ultimately left with having to deal with the condition and its 
consequences. As our review suggests, all is not lost by this 
stage and there is still scope for improvement even in the frail 
older person with a combination of measures.
The lack of diagnostic criteria to identify patients with 
sarcopenia hinders potential management options. Resistance 
exercise training remains the cornerstone of management for 
sarcopenia. As some older people are unable or unwilling to 
embark on exercise training program, alternative potential 
treatment options to counter the process of sarcopenia are 
being developed. Recent evidence has shown ACE inhibi-
tors can improve muscle exercise capacity in functionally 
impaired older people; however, further randomized con-
trolled trials are required. Other future prospects including 
the so called “exercise pill” have suggested potential methods 
to improve muscle performance in later life.
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